Clinical Trial Update: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating the efficacy and durability of Ampreloxetine for treating symptomatic neurogenic orthostatic hypotension in individuals with M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy
• Neurogenic Orthostatic Hypotension

Drugs mentioned

• Ampreloxetine (ampreloxetine)

Snippet

Sponsor: Theravance Biopharma | Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING